Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Treatment Experience and Predictive Factors Associated with Response in Platinum-Resistant Recurrent Ovarian Cancer: A Retrospective Single-Institution Study

Version 1 : Received: 16 May 2021 / Approved: 17 May 2021 / Online: 17 May 2021 (14:36:50 CEST)

How to cite: Dragomir, R.; Sas, I.; Săftescu, S.; Popovici, D.; Margan, R.; Dragomir, A.S.; Stanca, H.; Mocanu, V.; Pac, C.; Negru, Ș. Treatment Experience and Predictive Factors Associated with Response in Platinum-Resistant Recurrent Ovarian Cancer: A Retrospective Single-Institution Study. Preprints 2021, 2021050391 (doi: 10.20944/preprints202105.0391.v1). Dragomir, R.; Sas, I.; Săftescu, S.; Popovici, D.; Margan, R.; Dragomir, A.S.; Stanca, H.; Mocanu, V.; Pac, C.; Negru, Ș. Treatment Experience and Predictive Factors Associated with Response in Platinum-Resistant Recurrent Ovarian Cancer: A Retrospective Single-Institution Study. Preprints 2021, 2021050391 (doi: 10.20944/preprints202105.0391.v1).

Abstract

Ovarian cancer (OC) represents the most common and lethal gynecologic malignancy, due to its increased incidence and mortality rate. It is usually diagnosed in advanced stages and, even though surgery and platinum-based treatment are initially efficient, recurrences emerge in over 70% of cases. Although there are multiple options of chemotherapy drugs from which to choose, little is known regarding the best strategy for prolonged survival. Thus, the aim of this study was to assess the effect that most frequently used chemotherapeutic regimens have upon time-to-treatment-failure (TTF) from the first line and beyond, considering clinical and biological factors which influence the treatment outcome of platinum-resistant recurrent OC. We retrospectively analyzed data from 78 patients diagnosed with platinum-resistant OC, who underwent chemotherapy-based treatment with or without anti-angiogenic therapy at OncoHelp Oncology Center, Romania (January 2016 - February 2021). Our study identified positive predictive factors for TTF related to anthropometry (age over 60 for patients treated with topotecan with or without bevacizumab), renal function (creatinine levels between 0.65 and 1 mg/dl for patients treated with regimens containing bevacizumab and pegylated liposomal doxorubicin) and treatment choice (bevacizumab in combination with pegylated liposomal doxorubicin or topotecan used from the first line and beyond).

Keywords

ovarian cancer; platinum resistance; prognostic factors

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.